Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.

Laizure SC, Parker RB, Herring VL, Hu ZY.

Drug Metab Dispos. 2014 Feb;42(2):201-6. doi: 10.1124/dmd.113.054353. Epub 2013 Nov 8.

2.

Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.

Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O.

Drug Metab Dispos. 2014 Feb;42(2):250-6. doi: 10.1124/dmd.113.053561. Epub 2013 Nov 8.

3.

Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.

Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ.

Biochem Pharmacol. 2016 Nov 1;119:76-84. doi: 10.1016/j.bcp.2016.09.003. Epub 2016 Sep 8.

PMID:
27614009
4.
5.

Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.

Sato Y, Miyashita A, Iwatsubo T, Usui T.

Drug Metab Dispos. 2012 May;40(5):902-6. doi: 10.1124/dmd.111.043208. Epub 2012 Jan 31.

6.

In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.

Thomsen R, Rasmussen HB, Linnet K; INDICES Consortium.

Drug Metab Dispos. 2014 Jan;42(1):126-33. doi: 10.1124/dmd.113.053512. Epub 2013 Oct 18.

7.

Effects of alcohol on human carboxylesterase drug metabolism.

Parker RB, Hu ZY, Meibohm B, Laizure SC.

Clin Pharmacokinet. 2015 Jun;54(6):627-38. doi: 10.1007/s40262-014-0226-2.

8.

Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.

Hatfield MJ, Tsurkan L, Hyatt JL, Yu X, Edwards CC, Hicks LD, Wadkins RM, Potter PM.

Br J Pharmacol. 2010 Aug;160(8):1916-28. doi: 10.1111/j.1476-5381.2010.00700.x.

9.

Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.

Wang J, Williams ET, Bourgea J, Wong YN, Patten CJ.

Drug Metab Dispos. 2011 Aug;39(8):1329-33. doi: 10.1124/dmd.111.039628. Epub 2011 May 3.

10.

In vitro hydrolysis and transesterification of CDP323, an α4β1/α4β7 integrin antagonist ester prodrug.

Chanteux H, Rosa M, Delatour C, Prakash C, Smith S, Nicolas JM.

Drug Metab Dispos. 2014 Jan;42(1):153-61. doi: 10.1124/dmd.113.054049. Epub 2013 Oct 31.

11.

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.

Merali Z, Ross S, Paré G.

Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009. Review.

PMID:
24988246
12.

Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.

Ishizuka T, Yoshigae Y, Murayama N, Izumi T.

Drug Metab Dispos. 2013 Nov;41(11):1888-95. doi: 10.1124/dmd.113.053595. Epub 2013 Aug 14.

13.

Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.

Xu H, Majmudar JD, Davda D, Ghanakota P, Kim KH, Carlson HA, Showalter HD, Martin BR, Amidon GL.

Mol Pharm. 2015 Sep 8;12(9):3399-407. doi: 10.1021/acs.molpharmaceut.5b00414. Epub 2015 Aug 17.

14.

Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine.

Kim MJ, Jeong ES, Park JS, Lee SJ, Ghim JL, Choi CS, Shin JG, Kim DH.

Drug Metab Dispos. 2014 Jan;42(1):141-52. doi: 10.1124/dmd.113.053017. Epub 2013 Oct 29.

15.

Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.

Kobayashi Y, Fukami T, Shimizu M, Nakajima M, Yokoi T.

Drug Metab Dispos. 2012 Jun;40(6):1080-4. doi: 10.1124/dmd.112.044537. Epub 2012 Mar 23.

16.

Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.

Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, Rigas B.

J Pharmacol Exp Ther. 2012 Feb;340(2):422-32. doi: 10.1124/jpet.111.188508. Epub 2011 Nov 15.

17.

Contribution of human esterases to the metabolism of selected drugs of abuse.

Meyer MR, Schütz A, Maurer HH.

Toxicol Lett. 2015 Jan 5;232(1):159-66. doi: 10.1016/j.toxlet.2014.10.026. Epub 2014 Oct 24.

PMID:
25445008
18.

Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597.

Crow JA, Bittles V, Borazjani A, Potter PM, Ross MK.

Biochem Pharmacol. 2012 Nov 1;84(9):1215-22. doi: 10.1016/j.bcp.2012.08.017. Epub 2012 Aug 27.

19.

Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases.

Crow JA, Borazjani A, Potter PM, Ross MK.

Toxicol Appl Pharmacol. 2007 May 15;221(1):1-12. Epub 2007 Mar 12.

20.

Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.

Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS.

Biochem Pharmacol. 2009 Apr 1;77(7):1266-72. doi: 10.1016/j.bcp.2008.12.017. Epub 2009 Jan 6.

PMID:
19185566

Supplemental Content

Support Center